Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The conversation discusses a hair loss treatment regimen that includes a topical spray with finasteride and minoxidil, tretinoin, and using a Derminator (microneedling device) at 1.25mm depth every 5-6 days. The user reports positive results after 90 days and plans to continue the treatment, with others commenting on the process and potential outcomes.

Using the "big three" hair loss treatments (Minoxidil, Finasteride, and Ketoconazole) can initially make hair look worse, often causing dryness and a "straw" texture. Adjusting the routine with gentler shampoos and conditioners can improve hair appearance while waiting for the treatments to show results.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

The user is experiencing some hair regrowth after 3 months of using finasteride, minoxidil, biotin, vitamin C, and vitamin D, with noticeable improvements in hair thickness and baby hairs on the hairline. Other users suggest additional treatments like dermarolling and scalp massages for better results.

Using a combination of Stemoxydine, minoxidil, dutasteride, and keto shampoo to achieve extreme hair and beard growth. The user has experienced positive results with terminal hairs at the hairline and an increase in density to their stubble after several weeks of use.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

The conversation discusses a hair loss product containing Minoxidil, Finasteride, Azelaic Acid, and Caffeine. People are sharing their experiences and reviews of the product.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.